Just when the market was busy counting GLP-1 launch dates like astrologers predicting weddings, OneSource walked in and said, “Relax, we’re fully booked—but don’t trust our quarterly revenue.” Yes, a listed company openly admitting that numbers may not reflect reality. Rare. Slightly alarming. Definitely interesting.
Canada delays, court drama, semaglutide suspense, and accounting gymnastics—all packed into one concall. Management sounded confident, busy, and slightly irritated that Wall Street still loves neat spreadsheets.
They’re manufacturing every day, sold out on capacity, expanding aggressively, and yet politely warning investors: “Please don’t judge us by Q3 or Q4.”
If that sounds contradictory, congratulations—you’re paying attention. Read on. It gets spicier once capacity math, take-or-pay traps, and FY28 bravado enter the chat.
2. At a Glance
Revenue ₹3,758 cr (+12%) – Growth arrived, but not fast enough for impatient traders.